<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35386340</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">2452-199X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bioactive materials</Title>
          <ISOAbbreviation>Bioact Mater</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>15</StartPage>
          <EndPage>28</EndPage>
          <MedlinePgn>15-28</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bioactmat.2021.12.020</ELocationID>
        <Abstract>
          <AbstractText>The cytomembrane-derived delivery platform represents a promising biomimetic strategy in oncotherapy. To achieve durable and reliable tumor inhibition, mature dendrosomes (mDs), which were isolated from bone marrow-derived dendritic cells undergoing CT26 tumor antigen (TA) stimulation, were fused with redox-responsive nanoparticles (NPs) that were composed of poly(disulfide ester amide) polymers with an intensified disulfide density and hydrophobic oxaliplatin (OXA) prodrugs with the ability to potentiate immunogenicity. <i>In vitro</i> and <i>in vivo</i> results revealed that NP/mDs could induce tumor cell death through mitochondrial pathway and thus created immunogenic microenvironments, but also elicited immunocyte differentiation by TA cross-dressing and infiltration by direct presentation. By further neutralizing immune-regulatory interaction, the administration of PD-L1 antibody (αPD-L1) greatly improved antitumor efficiency of NP/mDs. Furthermore, the effectors of host immune systems effectively inhibited the growth and metastasis of distal tumors, likely because the autologous TA evoked by OXA and allogeneic TA delivered by mDs acted as additional stimuli to reinforce the immune response of tumor-speciﬁc T cells and immunosurveillance toward oncogenesis. These results demonstrated that NP/mDs could simultaneously realize immunogenic chemotherapeutics and specific TA delivery. In combination with αPD-L1, the antitumor effect was further enhanced. Therefore, NP/mDs provide a promising strategy for the comprehensive treatment of malignancy.</AbstractText>
          <CopyrightInformation>© 2021 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xing</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ling</LastName>
            <ForeName>Xiang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, State Key Laboratory of Natural Medicines, Nanjing, 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xia</LastName>
            <ForeName>Jiaxuan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Longlong</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Yuwei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Anni</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gu</LastName>
            <ForeName>Guolong</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Huashan Hospital, Fudan University, Shanghai, 200040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Jianxin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutics, School of Pharmacy, Fudan University, Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institutes of Integrative Medicine of Fudan University, Shanghai, 200040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bioact Mater</MedlineTA>
        <NlmUniqueID>101685294</NlmUniqueID>
        <ISSNLinking>2452-199X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antigen delivery</Keyword>
        <Keyword MajorTopicYN="N">Chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">Dendritic cell</Keyword>
        <Keyword MajorTopicYN="N">Dendrosome</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35386340</ArticleId>
        <ArticleId IdType="pmc">PMC8941172</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bioactmat.2021.12.020</ArticleId>
        <ArticleId IdType="pii">S2452-199X(21)00594-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Liu W.L., Zou M.Z., Liu T., Zeng J.Y., Li X., Yu W.Y., Li C.X., Ye J.J., Song W., Feng J., Zhang X.Z. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat. Commun. 2019;10(1):3199–3210. doi: 10.1038/s41467-019-11157-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-11157-1</ArticleId>
            <ArticleId IdType="pmc">PMC6642123</ArticleId>
            <ArticleId IdType="pubmed">31324770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu W.L., Zou M.Z., Liu T., Zeng J.Y., Li X., Yu W.Y., Li C.X., Ye J.J., Song W., Feng J., Zhang X.Z. Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv. Mater. 2019;31(18):1–10. doi: 10.1002/adma.201900499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201900499</ArticleId>
            <ArticleId IdType="pubmed">30907473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu C.M., Fang R.H., Wang K.C., Luk B.T., Thamphiwatana S., Dehaini D., Nguyen P., Angsantikul P., Wen C.H., Kroll A.V., Carpenter C., Ramesh M., Qu V., Patel S.H., Zhu J., Shi W., Hofman F.M., Chen T.C., Gao W., Zhang K., Chien S., Zhang L. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526(7571):118–121. doi: 10.1038/nature15373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15373</ArticleId>
            <ArticleId IdType="pmc">PMC4871317</ArticleId>
            <ArticleId IdType="pubmed">26374997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroll A.V., Jiang Y., Zhou J., Holay M., Fang R.H., Zhang L. Biomimetic nanoparticle vaccines for cancer therapy. Adv. Biosyst. 2019;3(1):1–17. doi: 10.1002/adbi.201800219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adbi.201800219</ArticleId>
            <ArticleId IdType="pmc">PMC6855307</ArticleId>
            <ArticleId IdType="pubmed">31728404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q., Huang G., Wu W., Wang J., Hu J., Mao J., Chu P.K., Bai H., Tang G. A hybrid eukaryotic-prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination. Adv. Mater. 2020;32(16):1–10. doi: 10.1002/adma.201908185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201908185</ArticleId>
            <ArticleId IdType="pubmed">32108390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X., Shen S., Fan Q., Chen G., Archibong E., Dotti G., Liu Z., Gu Z., Wang C. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci. Adv. 2019;5(10):1–10. doi: 10.1126/sciadv.aaw6870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aaw6870</ArticleId>
            <ArticleId IdType="pmc">PMC6810293</ArticleId>
            <ArticleId IdType="pubmed">31681841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt J.M., Andre F., Amigorena S., Soria J.C., Eggermont A., Kroemer G., Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 2016;126(4):1224–1232. doi: 10.1172/JCI81137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI81137</ArticleId>
            <ArticleId IdType="pmc">PMC4811123</ArticleId>
            <ArticleId IdType="pubmed">27035813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C., Boussac M., Veron P., Ricciardi-Castagnoli P., Raposo G., Garin J., Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J. Immunol. 2001;166(12):7309–7318. doi: 10.4049/jimmunol.166.12.7309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.166.12.7309</ArticleId>
            <ArticleId IdType="pubmed">11390481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 1998;4(5):594–600. doi: 10.1038/nm0598-594.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0598-594</ArticleId>
            <ArticleId IdType="pubmed">9585234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pitt J.M., Charrier M., Viaud S., Andre F., Besse B., Chaput N., Zitvogel L. Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J. Immunol. 2014;193(3):1006–1011. doi: 10.4049/jimmunol.1400703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1400703</ArticleId>
            <ArticleId IdType="pubmed">25049431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Besse B., Charrier M., Lapierre V., Dansin E., Lantz O., Planchard D., Le Chevalier T., Livartoski A., Barlesi F., Laplanche A., Ploix S., Vimond N., Peguillet I., Thery C., Lacroix L., Zoernig I., Dhodapkar K., Dhodapkar M., Viaud S., Soria J.C., Reiners K.S., Pogge von Strandmann E., Vely F., Rusakiewicz S., Eggermont A., Pitt J.M., Zitvogel L., Chaput N. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in nsclc. OncoImmunology. 2016;5(4):1–15. doi: 10.1080/2162402X.2015.1071008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1071008</ArticleId>
            <ArticleId IdType="pmc">PMC4839329</ArticleId>
            <ArticleId IdType="pubmed">27141373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou F., Feng B., Yu H., Wang D., Wang T., Ma Y., Wang S., Li Y. Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and cd47 blockade. Adv. Mater. 2019;31(14):1–11. doi: 10.1002/adma.201805888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201805888</ArticleId>
            <ArticleId IdType="pubmed">30762908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng B., Hou B., Xu Z., Saeed M., Yu H., Li Y. Self-amplified drug delivery with light-inducible nanocargoes to enhance cancer immunotherapy. Adv. Mater. 2019;31(40):1–10. doi: 10.1002/adma.201902960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201902960</ArticleId>
            <ArticleId IdType="pubmed">31423683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroemer G., Galluzzi L., Kepp O., Zitvogel L.  In: Immunogenic Cell Death in Cancer Therapy. Littman D.R., Yokoyama W.M., editors. 2013. pp. 51–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23157435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008;8(1):59–73. doi: 10.1038/nri2216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2216</ArticleId>
            <ArticleId IdType="pubmed">18097448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan X., Chan C., Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem. Int. Ed. Engl. 2019;58(3):670–680. doi: 10.1002/anie.201804882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201804882</ArticleId>
            <ArticleId IdType="pmc">PMC7837455</ArticleId>
            <ArticleId IdType="pubmed">30016571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling X., Chen X., Riddell I.A., Tao W., Wang J., Hollett G., Lippard S.J., Farokhzad O.C., Shi J., Wu J. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of pt(iv) prodrugs and reversal of cisplatin resistance. Nano Lett. 2018;18(7):4618–4625. doi: 10.1021/acs.nanolett.8b01924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b01924</ArticleId>
            <ArticleId IdType="pmc">PMC6271432</ArticleId>
            <ArticleId IdType="pubmed">29902013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S., Yu G., Wang Z., Jacobson O., Lin L.S., Yang W., Deng H., He Z., Liu Y., Chen Z.Y., Chen X. Enhanced antitumor efficacy by a cascade of reactive oxygen species generation and drug release. Angew Chem. Int. Ed. Engl. 2019;58(41):14758–14763. doi: 10.1002/anie.201908997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201908997</ArticleId>
            <ArticleId IdType="pubmed">31429173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y.X., Wang Y., An H.W., Qi B., Wang J., Wang L., Shi J., Mei L., Wang H. Peptide-based autophagic gene and cisplatin co-delivery systems enable improved chemotherapy resistance. Nano Lett. 2019;19(5):2968–2978. doi: 10.1021/acs.nanolett.9b00083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.9b00083</ArticleId>
            <ArticleId IdType="pubmed">30924343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T., Liu J., Liu M., Liu S., Zhao S., Tian R., Wei D., Liu Y., Zhao Y., Xiao H., Ding B. A nanobody-conjugated DNA nanoplatform for targeted platinum-drug delivery. Angew Chem. Int. Ed. Engl. 2019;58(40):14224–14228. doi: 10.1002/anie.201909345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201909345</ArticleId>
            <ArticleId IdType="pubmed">31389144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Y., Aimetti A.A., Langer R., Gu Z. Bioresponsive materials. Nat. Rev. Mater. 2016;2(1):17. doi: 10.1038/natrevmats.2016.75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/natrevmats.2016.75</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marin-Acevedo J.A., Dholaria B., Soyano A.E., Knutson K.L., Chumsri S., Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J. Hematol. Oncol. 2018;11(1):39–58. doi: 10.1186/s13045-018-0582-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-018-0582-8</ArticleId>
            <ArticleId IdType="pmc">PMC5856308</ArticleId>
            <ArticleId IdType="pubmed">29544515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hargadon K.M., Johnson C.E., Williams C.J. Immune checkpoint blockade therapy for cancer: an overview of fda-approved immune checkpoint inhibitors. Int. Immunopharm. 2018;62:29–39. doi: 10.1016/j.intimp.2018.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.06.001</ArticleId>
            <ArticleId IdType="pubmed">29990692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y., Li R., Li H., Zhang S., Dai W., Wu Q., Jiang L., Zheng Z., Shen S., Chen X., Zhu Y., Wang J., Pang Z. Erythroliposomes: integrated hybrid nanovesicles composed of erythrocyte membranes and artificial lipid membranes for pore-forming toxin clearance. ACS Nano. 2019;13(4):4148–4159. doi: 10.1021/acsnano.8b08964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsnano.8b08964</ArticleId>
            <ArticleId IdType="pubmed">30855941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakim L.M., Bevan M.J. Cross-dressed dendritic cells drive memory cd8+ t-cell activation after viral infection. Nature. 2011;471(7340):629–632. doi: 10.1038/nature09863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature09863</ArticleId>
            <ArticleId IdType="pmc">PMC3423191</ArticleId>
            <ArticleId IdType="pubmed">21455179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Ling X., Zhao L., Xiong F., Hollett G., Kang Y., Barrett A., Wu J. Biomimetic shells endow sub-50 nm nanoparticles with ultrahigh paclitaxel payloads for specific and robust chemotherapy. ACS Appl. Mater. Interfaces. 2018;10(40):33976–33985. doi: 10.1021/acsami.8b11571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsami.8b11571</ArticleId>
            <ArticleId IdType="pubmed">30203956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Zhao L., Kang Y., He Z., Xiong F., Ling X., Wu J. Significant suppression of non-small-cell lung cancer by hydrophobic poly(ester amide) nanoparticles with high docetaxel loading. Front. Pharmacol. 2018;9:1–11. doi: 10.3389/fphar.2018.00118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2018.00118</ArticleId>
            <ArticleId IdType="pmc">PMC5835838</ArticleId>
            <ArticleId IdType="pubmed">29541026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu T.T., Qi Y., Zhang D., Song Q.L., Yang C.L., Hu X.M., Bao Y.L., Zhao Y.D., Zhang Z.P. Bone marrow dendritic cells derived microvesicles for combinational immunochemotherapy against tumor. Adv. Funct. Mater. 2017;27(42):1–15. doi: 10.1002/adfm.201703191. ARTN 1703191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adfm.201703191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R., He Y., Zhu Y., Jiang L., Zhang S., Qin J., Wu Q., Dai W., Shen S., Pang Z., Wang J. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 2019;19(1):124–134. doi: 10.1021/acs.nanolett.8b03439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.nanolett.8b03439</ArticleId>
            <ArticleId IdType="pubmed">30521345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krysko D.V., Garg A.D., Kaczmarek A., Krysko O., Agostinis P., Vandenabeele P. Immunogenic cell death and damps in cancer therapy. Nat. Rev. Cancer. 2012;12(12):860–875. doi: 10.1038/nrc3380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3380</ArticleId>
            <ArticleId IdType="pubmed">23151605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Del Valle A., Anel A., Naval J., Marzo I. Immunogenic cell death and immunotherapy of multiple myeloma. Front. Cell Dev. Biol. 2019;7:1–22. doi: 10.3389/fcell.2019.00050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00050</ArticleId>
            <ArticleId IdType="pmc">PMC6476910</ArticleId>
            <ArticleId IdType="pubmed">31041312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leavy O. Antigen presentation: cross-dress to impress. Nat. Rev. Immunol. 2011;11(5):302–303. doi: 10.1038/nri2979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2979</ArticleId>
            <ArticleId IdType="pubmed">21508977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery C., Duban L., Segura E., Veron P., Lantz O., Amigorena S. Indirect activation of naive cd4+ t cells by dendritic cell-derived exosomes. Nat. Immunol. 2002;3(12):1156–1162. doi: 10.1038/ni854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni854</ArticleId>
            <ArticleId IdType="pubmed">12426563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L., Kim S., Herndon J.M., Goedegebuure P., Belt B.A., Satpathy A.T., Fleming T.P., Hansen T.H., Murphy K.M., Gillanders W.E. Cross-dressed cd8alpha+/cd103+ dendritic cells prime cd8+ t cells following vaccination. Proc. Natl. Acad. Sci. U. S. A. 2012;109(31):12716–12721. doi: 10.1073/pnas.1203468109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1203468109</ArticleId>
            <ArticleId IdType="pmc">PMC3411977</ArticleId>
            <ArticleId IdType="pubmed">22802630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robbins P.D., Morelli A.E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 2014;14(3):195–208. doi: 10.1038/nri3622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3622</ArticleId>
            <ArticleId IdType="pmc">PMC4350779</ArticleId>
            <ArticleId IdType="pubmed">24566916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Admyre C., Johansson S.M., Paulie S., Gabrielsson S. Direct exosome stimulation of peripheral human t cells detected by elispot. Eur. J. Immunol. 2006;36(7):1772–1781. doi: 10.1002/eji.200535615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.200535615</ArticleId>
            <ArticleId IdType="pubmed">16761310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oun R., Moussa Y.E., Wheate N.J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018;47(19):6645–6653. doi: 10.1039/c8dt00838h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c8dt00838h</ArticleId>
            <ArticleId IdType="pubmed">29632935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster R.G., Brain K.L., Wilson R.H., Grem J.L., Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br. J. Pharmacol. 2005;146(7):1027–1039. doi: 10.1038/sj.bjp.0706407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0706407</ArticleId>
            <ArticleId IdType="pmc">PMC1751225</ArticleId>
            <ArticleId IdType="pubmed">16231011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., Ogarra A., Murphy K.M. Development of th1 cd4+ t-cells through il-12 produced by listeria-induced macrophages. Science. 1993;260(5107):547–549. doi: 10.1126/science.8097338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.8097338</ArticleId>
            <ArticleId IdType="pubmed">8097338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thibaut R., Bost P., Milo I., Cazaux M., Lemaitre F., Garcia Z., Amit I., Breart B., Cornuot C., Schwikowski B., Bousso P. Bystander ifn-gamma activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Can. 2020;1(3):302–314. doi: 10.1038/s43018-020-0038-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-0038-2</ArticleId>
            <ArticleId IdType="pmc">PMC7115926</ArticleId>
            <ArticleId IdType="pubmed">32803171</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
